Press Releases
Page 6 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
WuXi Biologics Chengdu Microbial Manufacturing Site Reaches Structural Completion, Targets 2026 GMP Production
WuXi Biologics announces structural completion of its Chengdu microbial manufacturing facility with key equipment arrival, targeting GMP production by end 2026.
Quasar Medical Opens New Thailand Manufacturing Facility to Expand MedTech Production Capacity
Quasar Medical inaugurates new Chonburi manufacturing facility in Thailand, boosting global production capacity for interventional medical devices.
Daewoong Pharmaceutical NABOTA Master Class Highlights PrabotulinumtoxinA Safety for High-Dose Treatments
Daewoong Pharmaceutical hosted 74 healthcare professionals from 13 countries for NABOTA Master Class, emphasizing PrabotulinumtoxinA safety protocols.
Amcor Opens $35M Healthcare Packaging Facility in Malaysia to Strengthen Southeast Asia Medical Supply Chain
Amcor invests $35M in advanced healthcare packaging facility in Malaysia, bringing sterile medical packaging capabilities to Southeast Asia market.
Transcarent Partners with SmithRx to Expand Pharmacy Benefits Platform for Lower Drug Costs
Transcarent integrates SmithRx into its WayFinding platform to provide employers with enhanced pharmacy pricing transparency and reduced prescription drug costs.
HanchorBio Partners with Bloomberg to Enhance Drug Development Intelligence and Biopharma Strategy
HanchorBio selects Bloomberg's strategic intelligence platform to strengthen its immunotherapy drug development and global biopharma operations.
CatalYm Doses First Patient in Phase 2/3 Trial of Visugromab for Cancer Cachexia
CatalYm begins Phase 2/3 VINCIT trial of visugromab, an anti-GDF-15 antibody targeting cancer cachexia in 518 patients with advanced cancers worldwide.
Spinogenix Launches Phase 2b/3 CLARITY Trial of SPG601 for Fragile X Syndrome Treatment
Spinogenix initiates CLARITY Phase 2b/3 trial testing SPG601, a first-in-class oral therapy targeting BK channels for Fragile X Syndrome in male patients.
Samsung Bioepis Begins Phase 1 Trial for Novel ADC SBE303, Expands Sandoz Biosimilar Partnership
Samsung Bioepis launches first-in-human trial for ADC candidate SBE303 and expands Sandoz partnership for five biosimilars including vedolizumab.
Fosun Health Wins Three Awards at GlobalHealth Asia-Pacific Forum 2026, Showcases China Solution Strategy
Fosun Health strengthened its regional presence at GlobalHealth Asia-Pacific Forum 2026, winning three major awards while showcasing its China Solution approach.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
Calluna Pharma Completes CAL101 Phase 2 Enrollment for Idiopathic Pulmonary Fibrosis Treatment
Calluna Pharma enrolls 161 patients in Phase 2 AURORA study of CAL101 for IPF treatment, six months ahead of schedule with topline data expected Q1 2027.